|
Novel targeted therapy for pancreatic cancer
|
1R43CA221555-01A1
|
$299,979
|
HERRERA, VICTORIA
|
ABTELUM BIOMEDICAL, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
2R44CA200161-02A1
|
$1,000,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
Antibody targeting of ADAM8 for treatment of triple-negative breast cancer
|
3R41CA200161-01A1S3
|
$3,000
|
SONENSHEIN, GAIL
|
ADECTO PHARMACEUTICALS, INC.
|
|
A Novel Immunotherapy Targeting Cancer Stem Cells for the Treatment of Triple-Negative Breast Cancer
|
1R44CA224835-01A1
|
$298,864
|
PERICLE, FEDERICA
|
AGILVAX, INC.
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Core Support for Cancer Center
|
5P30CA013330-45
|
$3,646,138
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Arizona Cancer and Evolution Center (ACE)
|
1U54CA217376-01A1
|
$1,906,167
|
MALEY, CARLO
|
ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
|
|
Role of IRF8 in Tumor Rejection and Suppression
|
5R01CA133085-09
|
$307,800
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Role of NF-kB in Fas-mediated Apoptosis and Tumor Suppression
|
5R01CA182518-05
|
$315,400
|
LIU, KEBIN
|
AUGUSTA UNIVERSITY
|
|
Improving pathologic nodal staging of resected lung cancer
|
2R01CA172253-06
|
$499,347
|
OSAROGIAGBON, RAYMOND
|
BAPTIST MEMORIAL HOSPITAL - TIPTON
|
|
Role of Sympathetic Activation and RANKL/IL6 in Breast Cancer Bone Metastasis
|
5R01CA168717-05
|
$323,700
|
ELEFTERIOU, FLORENT
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and targeting oncogenic Myc enhancer control in pediatric tumors
|
3R01CA215452-02S1
|
$7,156
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
Identifying and Targeting Onocgenic MYC Enhancer Control in Pediatric Tumors
|
3R01CA215452-02S2
|
$45,800
|
LIN, CHARLES
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
5R01CA116548-13
|
$249,638
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S1
|
$118,333
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S2
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S3
|
$122,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-11S4
|
$250,002
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-11
|
$3,253,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-04
|
$2,300,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Translational Research in Breast Cancer (SPORE)
|
5P50CA186784-05
|
$2,251,410
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
Steroid Hormones Regulate Ovarian Cancer Progression and Metastasis
|
5R01CA181808-05
|
$336,565
|
RICHARDS, JOANNE
|
BAYLOR COLLEGE OF MEDICINE
|
|
Dissecting the molecular and functional role of ILK in driving metastatic colonization and progression in Ewing sarcoma
|
5R03CA215940-02
|
$75,288
|
YUSTEIN, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
MicroRNA Biomarkers for Determining Treatment Response in Colorectal Cancer
|
5R01CA202797-03
|
$349,694
|
GOEL, AJAY
|
BAYLOR RESEARCH INSTITUTE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
3U54CA209978-03S1
|
$125,000
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Combating Subclonal Evolution of Resistant Cancer Phenotypes
|
5U54CA209978-03
|
$2,154,776
|
BILD, ANDREA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S1
|
$73,297
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S2
|
$124,999
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
5P30CA033572-34
|
$2,446,682
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Multifunctional immunoPET tracers for pancreatic and prostate cancer
|
7R01CA174294-06
|
$377,890
|
WU, ANNA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Modulating systemic pro-oncogenic effects of focal image-guided tumor ablation
|
5R01CA197081-03
|
$470,573
|
AHMED, MUNEEB
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-13
|
$2,300,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-14
|
$2,300,000
|
MCDERMOTT, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Increased sensitivity of minimal residual disease monitoring using peripheral blood in pediatric patients with acute lymphoblastic leukemia
|
1R44CA224848-01A1
|
$348,768
|
MULLER, ROLF
|
BIOFLUIDICA, INC
|
|
BMX-001 as a Therapeutic Agent for Treatment of Multiple Brain Metastases.
|
1R44CA228694-01
|
$300,000
|
SILBERSTEIN, DAVID
|
BIOMIMETIX JV, LLC
|
|
Developing a translational pipeline for NF1-mutant malignancies
|
5U01CA202943-03
|
$235,046
|
CICHOWSKI, KAREN
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Dietary and Hormonal Determinants of Cancer in Women
|
5P01CA087969-18
|
$2,424,605
|
STAMPFER, MEIR
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Dietary and Hormonal Determinants of Cancer in Women
|
5P01CA087969-19
|
$2,402,014
|
STAMPFER, MEIR
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A novel small molecule FL7N-1 for treating pediatric cancer retinoblastoma
|
1R43CA221389-01A1
|
$224,919
|
LING, XIANG
|
CANGET BIOTEKPHARMA, LLC
|
|
Determining the Epigenetic Mechanisms Driving Tissue Factor (F3) Upregulation and its Role in Metastatic Osteosarcoma
|
5F31CA213965-02
|
$44,524
|
BAYLES, IAN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Treatment of glioblastoma using targeted nanoparticles
|
3U01CA198892-04S1
|
$66,200
|
COVARRUBIAS, GIL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Identification and Targeting of Chemotherapy Refractory Small Cell Lung Cancer
|
1R21CA226322-01
|
$208,800
|
DOWLATI, AFSHIN
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
2P30CA043703-28
|
$5,637,954
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|